Pudong's institutional innovation explores new paths

A glimpse of Shanghai Pudong. Source: China News Service
Shanghai, April 18 (By CNS Reporter Li Shuzheng)
April 18, 2025 was the 35th anniversary of Pudong's development. This frontier of China's reform is using institutional innovation to solve the shortcomings of enterprises and industries, and explore new paths for China's continued communication with the outside world.
Not long ago, two old Volvo hydraulic pumps were transported from Pudong International Airport to the remanufacturing workshop of Volvo Construction Equipment (China) Co., Ltd. This was the first bonded remanufacturing business outside the customs special supervision area in the country in Pudong, and also meant the start of the "bonded remanufacturing 2.0" era.
Bonded remanufacturing refers to the transportation of old foreign parts to domestic factories in a duty-free manner for disassembly and inspection in accordance with strict quality standards, and the assembly of the usable parts and new parts into remanufactured products, which are then shipped abroad for reuse. Compared with bonded maintenance, bonded remanufacturing has higher technical requirements, and the performance of the finished product is no less than that of a new product; at the same time, the benefits are more significant, and the cost and raw material consumption is greatly reduced by reusing parts. "Spend 50% of the money, save 40% on energy consumption, recycle 70% of materials, and reduce 80% of pollution - this is the '5678' rule of remanufacturing." Chen Chaoping, vice president of service and accessories at Volvo Construction Equipment (China) Co., Ltd., said.
Developing bonded remanufacturing is not only in line with the development of the circular economy and China's "dual carbon" strategy requirements, but also an important measure to promote the high-quality development of China's manufacturing industry in the direction of green and low-carbon. In the past, remanufactured products were classified as old electromechanical products, so some remanufactured products were included in the prohibited import catalog and could not pass customs normally. In response to this issue, Pudong relied on institutional innovation to open up a new path for the pilot import of remanufactured products in key industries. Volvo Construction Equipment (China) Co., Ltd. has become the first pilot enterprise in the country in this field.
Chen Chaoping said that bonded remanufacturing is the core link of Volvo Construction Equipment's global strategy. Currently, only Pudong has a remanufacturing base that meets standards in the Asia-Pacific region. The new breakthrough in bonded remanufacturing has effectively strengthened the functional positioning of the base as a regional industrial hub. After bonded remanufacturing businesses outside the customs special supervision area are opened, it is expected that more types of engineering machinery will enter Shanghai from all over the world for "re-manufacturing" in the future.
Similarly, through cross-departmental collaborative supervision and facilitation of customs clearance for special items, Pudong has solved the problem of cross-border flow of cell therapy products and explored a new way for cell therapy products to travel overseas.
In March 2025, a lymphoma patient received an injection of Fosun Kerry's CAR-T cell therapy drug in a Hong Kong hospital. This is the first cross-border transportation and use of CAR-T cell drugs in the country, and it is also an important achievement of Shanghai's first joint supervision mechanism for the entry and exit of special biomedical items.
CAR-T cell therapy is an innovative cancer treatment method - by collecting the patient's own T cells, after in vitro transformation and amplification, they are re-injected into the patient's body to accurately identify and attack cancer cells. However, this therapy has extremely strict temperature and time requirements for the transportation of blood samples and finished products, and the entry and exit chain involves multiple departments.
In order to promote the international innovation and coordinated development of the biopharmaceutical industry, Pudong took the lead in piloting the establishment of a joint supervision mechanism for the entry and exit of special biopharmaceutical items, and formulated management measures to promote the transformation of the "white list" pilot to conditional pilot management.
Chen Xingrong, CEO of Fosun Kerry, said that the joint supervision mechanism for the entry and exit of special biopharmaceutical items provides an efficient and safe solution for the cross-border transportation and supervision of cell therapy products, and also opens up a new path for cooperation between the mainland and Hong Kong in the field of biopharmaceuticals.
For 35 years, Pudong has continued to transform corporate needs into institutional supply and promote the deep connection between innovative practices and international standards. "Pudong will bravely serve as a pioneer in the new era of reform and development, expanding the high-level opening process, exploring the way to build a new development pattern, and empowering high-quality development,” said Wu Jincheng, mayor of Shanghai Pudong New Area. (End)
相关阅读

-
【异动股】Eden Innovations (ASX:EDE) 暴涨57%:美国数据中心客户OptiBlend kits订单持续放量

-
Pudong's scientific and technological innovation breeds hard-core new technologies

-
The 35th anniversary light show in Pudong, Shanghai outlines the future of innovation

-
【异动股】 LBT Innovations(ASX:LBT)与药企巨头阿斯利康达成重大交易(+20%)

-
移动支付平台PIL自2019年10月后首次复盘 股价大幅拉升

-
亚马逊创新大会被取消 澳洲会展经济或遭更大打击

-
亚洲坚果创新者通过全球首届澳洲坚果创新挑战赛展示全新

-
【异动股】NewPeak Metals(ASX:NPM)飙升40% 阿根廷Las Openas项目首孔发现大规模金-锌-银系统
免责声明:本网站信息仅供一般参考,不构成投资或财务建议。虽力求准确与完整,但不保证信息的准确性、完整性或时效性。投资有风险,决策前请咨询专业独立顾问。使用本网站即视为接受本免责声明。
热门点击
-
- 金融机构违规成为ASIC执法查处重点 CFD发行商Union Standard及前授权代表遭罚3.002亿澳元 创纪录罚款
-
- The Star Entertainment(ASX: SGR)FY26Q4季报:流动性危机暂解 主业仍未走出底部
-
- 【异动股】非中国稀土供应链打造遭遇现实瓶颈 Lynas马来西亚重稀土产能扩建资本开支预算陡升 股价盘中急跌逾8%
-
- 【公司观察】从资源到现金流 Lithium Plus Minerals Ltd.(ASX:LPM)直运矿战略将如何重塑锂矿开发模式(1)
-
- 毕马威澳洲因审计丑闻拟裁员近1000人 数十名合伙人面临出局
-
- 【7.29】今日财经时讯及重要市场资讯
-
- 就业韧性与通胀黏性共存 澳储行八月会议悬念陡增 市场押注年内将迎第四次加息
-
- 【7.20】今日财经时讯及重要市场资讯
-
- 创始人50亿股限售股解禁将至 澳药房巨头Sigma Healthcare(ASX:SIG)股价面临短期流动性大考 8月27日财报日迎压力测试
-
- 中国外汇管理局严厉打击地下钱庄等外汇违法违规活动 上半年相关罚没款超4亿元
-
- Treasury Wine Estates(ASX:TWE)暂停对华供应奔富Bin 407三个月 深入整顿渠道灰色市场
-
- 新旧财年交替 澳股市场迎板块轮动 医疗与消费超跌龙头集体修复 科技股获资金回涌
-
- 财报季=裁员季?16家ASX公司面临成本削减大考 薪资剪刀差与AI冲击持续考验生存韧性
-
- 兖煤澳洲Yancoal Australia (ASX:YAL)Q2季度商品煤产量创新高 年产量预计达指导区间上段 Kestrel煤矿收购获FIRB批准收官在望
-
- 澳股FY2026收官:主要指数全线收涨 资源板块领跑全年 科技医疗明显承压

